Last reviewed · How we verify

NCT04324294

Contrast Enhanced Endoscopic Ultrasound in Pancreas Lesions

Status unknown Phase 1 Last updated 20 December 2023
What this trial tests

Phase 1 trial testing EUS enhanced with contrast to evaluate pancreas in Pancreatitis in 200 participants. Status unknown.

Timeline
26 February 2020
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorCedars-Sinai Medical Center
PhasePhase 1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment200
Start date26 February 2020
Primary completion31 December 2025
Estimated completion31 December 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Cedars-Sinai Medical Center

Who can join

18 and older, any sex, with Pancreatitis or Pancreas Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether quantitative contrast-enhanced endoscopic ultrasound (CE-EUS) improves the evaluation of pancreas tumors and precursor lesions, including cysts, compared to conventional endoscopic ultrasound.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pancreatitis

Currently open trials in the same condition.

Other Cedars-Sinai Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04324294.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing